GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Tedizolid phosphate (Sivextro)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

SIVEXTRO - adult ABSSSI dosing

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method
No renal-function dose bands specified for this summary.
Source revision
DailyMed updated 2026-02-27.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Official

SIVEXTRO - adult ABSSSI dosing

Open original reference

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2026-02-27.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult acute bacterial skin/skin-structure infection: 200 mg orally or IV once daily for 6 days. Give IV doses over 1 hour. IV-to-oral conversion does not change the dose. No renal adjustment is required, including during hemodialysis; dialysis does not meaningfully remove tedizolid.

Longer treatment is not the labeled course. Consider hematologic monitoring for prolonged off-label therapy. This adult card does not reproduce the label's separate pediatric weight-based schedules.

RDM30-077-tedizolid-1 · Source locator: SIVEXTRO - adult ABSSSI dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75672079-589f-451a-bdbf-eaebcfcc80a9
Retrieved
2026-09-05
DailyMed Set ID
75672079-589f-451a-bdbf-eaebcfcc80a9
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2026-02-27.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
6c774b07076be5513d6f2c7d596b5c51c38ba3feb1498c2465a484b192ec1251

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=tedizolid&s1=RDM30-077-tedizolid&h1=58365f5c921fd5a88a9ac95e405c980d71d03ff51eef0495c82e20147efcec5e